Poster Abstracts • OFID 2018:5 (Suppl 1) • S539 low-risk group (18% vs. 8%, 10% absolute risk difference), followed by the medium (24% vs. 18%, 6% difference) and high (39% vs. 33%, 6% difference) risk groups. PCT was associated with higher 30-day mortality than PMT overall (aOR, 1.54; 95% CI, 1.43-1.66), and in all three groups: low (aOR, 1.69; 95% CI, 1.50-1.89), medium (aOR, 1.30; 95% CI, 1.14-1.48), and high (aOR, 1.21; 95% CI, 1.04-1.40).
Background. Empiric antibiotic treatment of serious and healthcare-associated pneumonia (PNA) often includes coverage of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PSA). Recent publications suggest that patients treated with the combination of vancomycin (V) and piperacillin-tazobactam (PT) have a greater risk of acute kidney injury (AKI) than those treated with V alone, or V in combination with another β-lactam, such as cefepime (C). There is a paucity of data regarding the risk of AKI in other regimens that provide MRSA and PSA coverage, such as linezolid (L)-PT or LC. We examined the incidence of nephrotoxicity in patients who received combination antibiotic therapy for PNA.
Methods. A retrospective cohort analysis of eligible adult patients (≥18 years) admitted from July 1, 2014 to June 30, 2017 who received ≥48 hours of combination therapy was conducted. Patients were excluded if their baseline serum creatinine was ≥1.4 mg/dL, on renal replacement therapy, or if diagnosed with cystic fibrosis. The primary outcome was incidence of AKI as defined by RIFLE criteria. Comparisons between the groups were analyzed by chi-squared test. To identify variables associated with AKI in a multivariable analysis, a repeated measures, mixed-effects logistic regression was utilized.
Results. There were 185 patient encounters included in the analysis. RIFLEdefined AKI occurred in treatment groups as follows: VPT 31/98 (31.6%); VC 5/50 (10.0%); LPT 4/12 (33.3%); and LC 4/25 (16.0%). There was a significant difference in rates of AKI among the four groups (P = 0.019). In pooled analyses, no difference was identified between patients receiving V or L (P = 0.73); however, patients who received PT had a higher incidence of AKI compared with those that received C (P = 0.002). In logistic regression analyses, independent predictors of AKI were receipt of PT vs. C (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.3-8.0) and SOFA score ≥9 (OR, 4.5; 95% CI 1.6-12.7).
Conclusion. No differences in AKI incidence were found between patients receiving vancomycin or linezolid; however, patients receiving piperacillin-tazobactam and those with SOFA scores ≥9 had a higher rate of AKI.
Disclosures. Background. Recent data suggest antibiotic-related harm occurs in 1 in 5 hospitalized patients. The purpose of this study was to critically evaluate potential adversedrug-events (ADE) associated with antimicrobial administration in hospitalized family medicine (FAM) patients.
Methods. Retrospective cohort of adults receiving antimicrobial therapy for respiratory, urinary, and skin infection on an inpatient FAM ward between January 2017 and March 2018. Primary endpoint: potential ADEs up to 30-day post-therapy, identified using inpatient and outpatient electronic medical records. ADEs were classified as mild, moderate, or severe; Naranjo scores were used to classify causality. Other endpoints included risk associated with ADE, subsequent 30-day readmissions, and infections due to multidrug-resistant organisms up to 90-days post-therapy.
Results. 1,499 antibiotic days were assessed in 150 hospitalized adults. Fifty-four patients with at least one potential ADE (68 total) were identified. By Naranjo score, 10 (6.7%) patients had "probable" antibiotic related ADEs (score 5-8), all others were "possible" (score 1-4). Excluding patients with diarrhea receiving concomitant laxatives, 36 patients (24%) suffered from 50 potential ADEs, approximately 3.33 per 100 antibiotic days (Table 1) . Thirteen (9.3%) had serious ADEs; 6 were receiving concomitant medications which may have contributed to harm, primarily nephrotoxins (5/6). Alteration of antimicrobial therapy was attributed to ADEs in 12/54 cases (22.2%) while 6 (11.1%) led to 30-day hospital or emergency department (ED) revisits. ADEs were not associated with any specific antimicrobial. Patients with ADEs were more likely to have ED/hospital revisits (OR = 2.42 [1. .05]) and receive more total antibiotic days (11 [6-15] vs. 8 days [6-12 days], P = 0.036) compared with those who did not.
Conclusion. One in four hospitalized FAM patients receiving antimicrobials experienced potential ADE. While varying in nature and severity, antimicrobial ADEs contribute to serious harm. These findings underscore need for improved awareness and judicious use.
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